Two EU-funded Consortium Grants for PhD training at GenomeScan
GenomeScan has been granted two Marie Skłodowska-Curie Actions within the Innovative Training Network calls of the European Union-funded Horizon 2020 Program. These PhD traineeships are part of Horizon 2020 Grants acquired by two different Consortia where Academia and Industry collaborate closely together. Recruitment of PhD candidates with a focus on Bioinformatics will start near the end of 2019 (applications are welcome as of today).
The proEVLifeCycle Project (ID 860303) aims to study the life cycle of extracellular vesicles in prostate cancer – from biogenesis and homing, to functional relevance. Prostate cancer presents as a major health care problem for men, with EU-wide approximately 365,000 new cases annually (reference https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe). Current means to identify rapid from slow progressing tumors are lacking specificity. There is an unmet need to means of non-invasive discrimination of these tumors and identification of novel targets for therapeutic intervention of high-risk tumors. The proEVLifeCycle Project will aid to the understanding of prostate cancer progression and consequently, to the implementation of novel biomarkers and therapeutic interventions to have a lasting impact on this indiscriminate and lethal disease.
The goal of the TrainCDKis Project (ID 860977) is to provide a multidisciplinary training programme to top-level young scientists to develop creative solutions for chronic kidney disease – from genetic modifiers to drug discovery. Chronic kidney disease is characterized by the progressive decline of renal function, associated with impaired quality of life and reduced life expectancy. It affects 10-15% of the worldwide population and is recognized as an increasing global health problem with a substantial burden on health-care budgets. The research projects within TrainCKDis will address key challenges focusing at genetic and epigenetic modifiers able of identifying patients that are predisposed to disease progression, biomarkers for disease monitoring and identification of novel therapeutic targets to impact the limited treatment options.
